Shandong Keyuan Pharmaceutical 과거 수익 실적
과거 기준 확인 1/6
Shandong Keyuan Pharmaceutical has been growing earnings at an average annual rate of 7.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.5% per year. Shandong Keyuan Pharmaceutical's return on equity is 3.7%, and it has net margins of 11.5%.
주요 정보
7.8%
수익 성장률
0.7%
EPS 성장률
| Pharmaceuticals 산업 성장 | 10.9% |
| 매출 성장률 | 7.5% |
| 자기자본 수익률 | 3.7% |
| 순이익 | 11.5% |
| 최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
수익 및 비용 분석
Shandong Keyuan Pharmaceutical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 438 | 50 | 101 | 36 |
| 30 Jun 24 | 460 | 62 | 103 | 44 |
| 31 Mar 24 | 470 | 66 | 108 | 45 |
| 31 Dec 23 | 448 | 77 | 100 | 44 |
| 30 Sep 23 | 449 | 89 | 91 | 41 |
| 30 Jun 23 | 443 | 91 | 85 | 32 |
| 31 Mar 23 | 454 | 96 | 69 | 30 |
| 01 Jan 23 | 443 | 91 | 57 | 27 |
| 01 Jan 22 | 421 | 78 | 63 | 24 |
| 31 Dec 20 | 367 | 69 | 71 | 28 |
| 31 Dec 19 | 311 | 30 | 62 | 31 |
| 30 Sep 19 | 301 | 46 | 55 | 17 |
| 30 Jun 19 | 265 | 53 | 26 | 12 |
| 31 Mar 19 | 261 | 44 | 34 | 11 |
| 31 Dec 18 | 271 | 20 | 56 | 11 |
| 30 Sep 18 | 266 | 31 | 46 | 8 |
| 30 Jun 18 | 260 | 34 | 41 | 7 |
| 31 Mar 18 | 249 | 46 | 29 | 0 |
| 31 Dec 17 | 239 | 44 | 27 | 7 |
| 30 Sep 17 | 218 | 40 | 26 | 5 |
| 30 Jun 17 | 196 | 36 | 25 | 2 |
| 31 Mar 17 | 183 | 32 | 27 | 0 |
| 31 Dec 16 | 180 | 33 | 24 | 0 |
| 30 Sep 16 | 167 | 29 | 24 | 0 |
| 30 Jun 16 | 155 | 25 | 23 | 0 |
| 31 Mar 16 | 139 | 20 | 21 | 0 |
| 31 Dec 15 | 123 | 14 | 19 | 0 |
| 31 Dec 14 | 133 | 9 | 16 | 0 |
| 31 Dec 13 | 133 | 1 | 22 | 0 |
양질의 수익: 301281 has a high level of non-cash earnings.
이익 마진 증가: 301281's current net profit margins (11.5%) are lower than last year (19.8%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 301281's earnings have grown by 7.8% per year over the past 5 years.
성장 가속화: 301281's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
수익 대 산업: 301281 had negative earnings growth (-43.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
자기자본 수익률
높은 ROE: 301281's Return on Equity (3.7%) is considered low.